Beactica is a specialist drug discovery company utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform and services in the area of SPR biosensor-based interaction analysis, e.g. kinetic characterization and evaluation of binding mechanism.

Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as the leader in SPR biosensor-based small molecule drug discovery with experience of a wide range of different protein drug target types.

For screening and characterization services, see here.

Press releases


Upcoming events

7–10 January 2019, Beactica holds meetings in conjunction with the 37th Annual JP Morgan Healthcare Conference in San Francisco, USA.